Cancer Immunology, Immunotherapy

, Volume 11, Issue 2, pp 93–96 | Cite as

Positive skin tests with autologous tumor cells of increased membrane viscosity

First report
  • Y. Skornick
  • E. Danciger
  • R. R. Rozin
  • M. Shinitzky
Original Articles


Skin tests were carried out with irradiated autologous tumor cells in patients with solid tumors (large-bowel carcinoma, gastric carcinoma, malignant melanoma, and breast cancer). With untreated cells, the skin reaction was negative or very weakly positive. A strong skin reaction, however, was elicited with cells of elevated membrane lipid microviscosity. This was induced by incorporation of cholesterol or, more effectively, by cholesterly hemisuccinate (CHS). A fair correlation was observed between the level of skin reaction with CHS-treated cells and the clinical stage of the tumor. It is suggested that rigidification of the cell membrane lipid layer exposes latent tumor-associated antigens, which enhances the cell-specific tumor immunogenicity. CHS-treated cells could therefore be of clinical value in active immunotherapy of human cancer.


Malignant Melanoma Skin Test Skin Reaction Positive Skin Test Cell Membrane Lipid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adler A, Stein JA, Czernobilsky B (1978) Induction of cutaneous W.H.R. to irradiated autologous tumor cells in inoperable breast cancer. In: Proceedings of the Third International DePCa Symposium New York, 1976, Marcel Dekker, New York, p 573Google Scholar
  2. 2.
    Bartlett LG, Zbar B (1972) Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst 48:1709Google Scholar
  3. 3.
    Borochov H, Shinitzky M (1976) Vertical displacement of membrane proteins mediated by changes in microviscosity. Proc Natl Acad Sci USA 73:4526Google Scholar
  4. 4.
    Byers VS, Baldwin RW (1979) Modulation of tumor cell membranes with lipophilic haptens: An approach to modifying tumor immunogenicity. In: Bach FH, Bonavida B, Vitetta FS, Fox CF (eds) T and B lymphocytes, recognition and function. Academic Press, New York, p 603Google Scholar
  5. 5.
    Currie GA, McElwain TG (1975) Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer 31:143Google Scholar
  6. 6.
    Hughes LE, Lytton B (1964) Antigenic properties of human tumors: Delayed cutaneous hypersensitivity reactions. Br Med J 1:209Google Scholar
  7. 7.
    Morton DL, Eibler FR, Joseph WL, Wood WC, Trahan E, Ketcham AS (1971) Immunological aspects of neoplasia: A rotational basis for immunotherapy. Ann Intern Med 74:587Google Scholar
  8. 8.
    Oldham RK, Herberman RB (1979) Cell-mediated immunity to tumor-associated antigens; In: Herberman RB, McIntire KB (eds) Immunodiagnosis of cancer, vol 9 part 2. Marcel Dekker, New York, p 940Google Scholar
  9. 9.
    Oldham RK, Weese JL, Heberman RB, Perlin E, Mills M, Heim W, Blom J, Green P, Reid J, Bellinger S, Law I, McCoy JL, Dean JH, Cannon GV, Djeu J (1976) Immunological monitoring and immunotherapy in carcinoma of the lung. Int J Cancer 18:739Google Scholar
  10. 10.
    Oren ME, Herberman RB (1971) Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumor cells. Clin Exp Immunol 9:45Google Scholar
  11. 11.
    Shearer GM, Schmitt-Verhulst AM (1977) Major histocompatibility complex restricted cell-mediated immunity. Adv Immunol 25:55Google Scholar
  12. 12.
    Shinitzky M (1976) Membrane changes in malignant cells — Modulation of receptors and antigens by lipids. Bull Schweiz Akad Med Wiss 32:203Google Scholar
  13. 13.
    Shinitzky M, Skornik Y, Haran-Ghera N (1979) Effective tumor immunization induced by cells of elevated membrane-lipid microviscosity. Proc Natl Acad Sci USA 76:5313Google Scholar
  14. 14.
    Stein JA, Adler A, Goldfarb AJ, Czernobilsky B (1978) Direct endolymphatic instillation of BCG-tumor cell-mixture. Cancer Immunol Immunother 5:31Google Scholar
  15. 15.
    Stein JA, Adler A, Czernobilsky B, Goldfarb AJ, Rozin RR, Teva Z, Stavorovsky M (1979) Cutaneous response to autochthonous tumor cells in breast cancer and melanoma by active immunization. In: TAA and their immune response. Academic Press, London, p 343Google Scholar
  16. 16.
    Stewart THM (1969) The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. I. The role of tissue antigen, nonspecific reaction of nuclear material and bacterial antigen as a cause for this phenomenon. Cancer 23:1368Google Scholar
  17. 17.
    Weese JL, Oldham RR, Tormey DC, Barlock AL, Movales A, Cohen MH, Alford TC, Shorb PE, Tsangaris NT, West WH, Cannon GB, Dean JH, Djeu J, McCoy JL, Herberman RB (1977) Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet 145:208Google Scholar
  18. 18.
    Zinkernagel RM, Doharty PC (1979) MHC-restrictrd cytotoxic T-cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction specificity, function and responsiveness. Adv Immunol 27:52Google Scholar

Copyright information

© Springer-Verlag GmbH & Co KG 1981

Authors and Affiliations

  • Y. Skornick
    • 1
  • E. Danciger
    • 2
  • R. R. Rozin
    • 1
  • M. Shinitzky
    • 2
  1. 1.Department of SurgeryRokach HospitalTel Aviv
  2. 2.Department of Membrane ResearchThe Weizmann Institute of ScienceRehovotIsrael

Personalised recommendations